Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at

Analysts at began coverage on shares of Organovo (NASDAQ:ONVOGet Rating) in a research note issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Organovo stock opened at $2.94 on Monday. The business’s 50-day simple moving average is $2.39 and its 200 day simple moving average is $2.94. The stock has a market cap of $25.61 million, a price-to-earnings ratio of -2.24 and a beta of 0.76. Organovo has a 12-month low of $1.71 and a 12-month high of $8.30.

Organovo (NASDAQ:ONVOGet Rating) last posted its quarterly earnings results on Friday, June 10th. The medical research company reported ($0.22) earnings per share (EPS) for the quarter. The company had revenue of $1.50 million during the quarter.

Hedge Funds Weigh In On Organovo

An institutional investor recently bought a new position in Organovo stock. Prescott Group Capital Management L.L.C. bought a new stake in Organovo Holdings, Inc. (NASDAQ:ONVOGet Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 55,170 shares of the medical research company’s stock, valued at approximately $200,000. Prescott Group Capital Management L.L.C. owned 0.63% of Organovo at the end of the most recent quarter. Institutional investors own 26.03% of the company’s stock.

Organovo Company Profile

(Get Rating)

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Read More

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with's FREE daily email newsletter.